Edwards Lifesciences Co. (NYSE:EW – Get Rating) VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $90.94, for a total value of $611,571.50. Following the completion of the transaction, the vice president now owns 62,561 shares in the company, valued at approximately $5,689,297.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Edwards Lifesciences Stock Performance
Shares of EW stock opened at $97.25 on Friday. Edwards Lifesciences Co. has a 12-month low of $85.58 and a 12-month high of $131.73. The company has a market cap of $60.29 billion, a price-to-earnings ratio of 42.10, a price-to-earnings-growth ratio of 2.81 and a beta of 1.14. The stock has a 50 day simple moving average of $98.52 and a 200-day simple moving average of $103.02. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10.
Edwards Lifesciences (NYSE:EW – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.51 EPS for the current year.
Analyst Ratings Changes
Hedge Funds Weigh In On Edwards Lifesciences
Hedge funds have recently bought and sold shares of the company. American National Bank increased its stake in Edwards Lifesciences by 99.1% in the 1st quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 116 shares in the last quarter. Core Alternative Capital increased its position in Edwards Lifesciences by 513.2% during the first quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock worth $27,000 after buying an additional 195 shares in the last quarter. Rinkey Investments purchased a new position in Edwards Lifesciences during the fourth quarter worth $29,000. JJJ Advisors Inc. increased its position in Edwards Lifesciences by 79.1% during the first quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company’s stock worth $33,000 after buying an additional 125 shares in the last quarter. Finally, Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the second quarter worth $28,000. 81.33% of the stock is owned by hedge funds and other institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.